SCHEMBL10276098

SCHEMBL10276098

N#Cc1ccc(C2=NC(=O)n3nc(-c4ccccc4C(F)(F)F)c(-c4ccc(F)cc4F)c32)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.35
NSD2 O96028 1/20 0.35
AR P10275 2/20 0.34
HSD11B1 P28845 3/20 0.33
RXRA P19793 1/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
ADORA1 P30542 2/20 0.32
BRAF P15056 1/20 0.32
KDR P35968 1/20 0.32
NR3C1 P04150 1/20 0.32
PGR P06401 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
ADORA2A P29274 1/20 0.32
MAOB P27338 1/20 0.32
USP1 O94782 2/20 0.32
WDR48 Q8TAF3 2/20 0.32
KDM1A O60341 1/20 0.32
ALOX5AP P20292 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275608 0.88 ADORA1 (0.42) NSD2ARADORA1BRAFKDR
SCHEMBL10276100 0.87 KIF11 (0.39) KIF11NSD2ARADORA1BRAF
SCHEMBL10275913 0.86 KIF11 (0.35) KIF11NSD2ARHSD11B1RXRA
SCHEMBL10275329 0.84 ARF6 (0.37) KIF11NSD2ARBRAFKDR
SCHEMBL10275390 0.82 AR (0.37) NSD2ARBRAFKDRPGR
SCHEMBL10276342 0.80 NPSR1 (0.44) KIF11ADORA1BRAFKDRADORA2A
SCHEMBL10275747 0.78 GABRG2 (0.36) NSD2ARRXRAPDE3BPDE3A
SCHEMBL10276213 0.77 KDM1A (0.37) ARPDE3BPDE3AKDM1A
SCHEMBL10276001 0.74 AR (0.38) KIF11ARADORA1ADORA2AMAOB
SCHEMBL10275596 0.73 PGR (0.38) KIF11BRAFKDRPGRPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 KIF11 4069/4885NSD2 3880/4885AR 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.